We previously showed that miR-491-5p [9] and miR-3622b-5p [10] directly target Bcl-xL and EGFR in ovarian cancer cells, and that the combined use of Bcl-xL and EGFR inhibitors, respectively, in clinical trials (ABT-263), which are FDA-approved for the treatment of non-small-cell lung cancer (gefitinib), could efficiently recapitulate the cytotoxicity induced by both of these miRNAs. The gene discussed is BCL2L1; the disease is ovarian cancer.